Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base

NCT07145931 · tracked via the Priya Life Science China tracker

Sponsor

Sun Yat-sen University

Phase

Phase 2

Started

2025-09-20

Last updated

2025-08-28

Condition(s) studied

Head and Neck Cancer Squamous Cell CarcinomaSkull Base--CancerNeoadjuvant ChemoimmunotherapyObjective Response Rate

Investigational drug(s) / intervention(s)

Neoadjuvant chemoimmunotherapyTislelizumab Nab paclitaxel →

Neoadjuvant chemoimmunotherapy: * Neoadjuvant therapy is administered every 3 weeks (Tislelizumab 200mg D1, Nab Paclitaxel 260mg/m² D1, Cisplatin 75mg/m² D1-3) for a total of 3 cycles. * Surgical treatment is performed within 3 weeks after completing neoadjuvant therapy. * Postoperative (chemo)radiotherapy is initiated 4-6 weeks after surgery. * Following (chemo)radiotherapy, adjuvant immunotherapy (Tislelizumab 200mg) is administered every 3 weeks for a total of 8 cycles.

Tislelizumab Nab paclitaxel: Neoadjuvant therapy is administered every 3 weeks (Tislelizumab 200mg D1, Nab Paclitaxel 260mg/m² D1, Cisplatin 75mg/m² D1-3) for a total of 3 cycles.

Study summary

This prospective, single-arm, Phase II clinical trial aims to evaluate the efficacy and safety of tislelizumab combined with chemotherapy as neoadjuvant therapy and postoperative adjuvant immunotherapy in patients with skull base-invading head and neck squamous cell carcinoma. The primary objectives are to address the following questions:

* What are the objective response rate and pathological response of tislelizumab combined with chemotherapy as neoadjuvant therapy in patients with skull base-invading head and neck squamous cell carcinoma?
* Can neoadjuvant therapy convert unresectable skull base-invading head and neck squamous cell carcinoma into a resectable condition?
* Can adjuvant immunotherapy after neoadjuvant therapy prolong patients' recurrence-free survival and overall survival? The researchers will administer neoadjuvant therapy (tislelizumab combined with chemotherapy) and adjuvant immunotherapy to patients with skull base-invading head and neck squamous cell carcinoma and assess the treatment's efficacy and safety.

Participants will:

* Receive neoadjuvant therapy every 3 weeks (tislelizumab 200mg on Day 1, nab-paclitaxel 260mg/m² on Day 1, cisplatin 75mg/m² on Days 1-3) for 3 cycles.
* Undergo surgical treatment within 3 weeks after completing neoadjuvant therapy.
* Receive (chemo)radiotherapy 4-6 weeks after surgery.
* Receive adjuvant immunotherapy (tislelizumab 200mg) every 3 weeks after (chemo)radiotherapy for 8 cycles.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Age 18 to 80 years, regardless of gender; * Histologically confirmed squamous cell carcinoma (including gingiva, buccal mucosa, palate, oropharynx, maxillary sinus, or maxilla/mandible) with radiological evidence of skull base invasion; * Measurable tumor lesions (meeting RECIST v1.1 criteria); * Treatment-naïve primary T4b-stage patients (N any, per AJCC 8th Edition, 2017); * ECOG PS score: 0-1; * Medically fit for surgery and chemotherapy, with no surgical contraindications; * Women of childbearing potential (18-49 years) must have a negative pregnancy test within 7 days before treatment. Sexually active men and women must agree to use effective contraception during the trial and for 3 months after treatment cessation; * Willing to provide written informed consent and comply with scheduled follow-ups, treatments, lab tests, and other study requirements. Exclusion Criteria: * Previous anti-tumor treatments including chemotherapy, radiotherapy, or immunotherapy; Refusal to sign informed consent; * Patients who refuse the study treatment protocol; patients unable to complete treatment as planned; or patients unable to comply with regular follow-up due to psychological, social, familial or geographical reasons; * Patients with known allergies to any study medications; * Patients with poor systemic conditions unfit for treatment: as determined by routine tests (complete blood count, blood biochemistry, ECG, chest X-ray, etc.). Poor systemic conditions include: hemoglobin \<60g/L, WBC \<3.0×10⁹/L, platelets \<80×10⁹/L, or serum creatinine \>133μmol/L - such patients may be recommended for conservative treatment; * Patients with autoimmune diseases requiring long-term immunosuppressive or corticosteroid therapy; * Pregnant or lactating women (pregnancy testing should be considered for sexually active women of childbearing potential); * Patients with current or previous malignancies (except adequately treated non-melanoma skin cancer, cervical carcinoma in situ, or papillary thyroid carcinoma); * Participation in other clinical trials within 30 days prior to enrollment; * Other conditions that may compromise patient safety or compliance as assessed by investigators, including: severe comorbidities (including psychiatric disorders), significantly abnormal laboratory results, or other high-risk familial/social factors.

Primary outcome measure(s)

Objective response rate — Within 3 weeks after completion of neoadjuvant therapy
Objective Response Rate (ORR) is a pivotal efficacy endpoint in oncology therapeutic evaluation, defined as the proportion of patients whose tumor burden shrinks to a prespecified threshold (achieving either complete or partial response). This metric is measured using internationally standardized criteria (RECIST 1.1), with radiographic imaging to monitor changes in the sum of target lesion diameters. Based on Standardized Criteria (e.g., RECIST 1.1). Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): ≥30% decrease in tumor size (sum of target lesions). ORR = CR + PR (expressed as a percentage).

Trial sites (1)

Facility	City	Region	Status
Hospital of Stomatology, Sun Yat-sen University	Guangzhou	Guangdong

More Sun Yat-sen University trials in China

Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma. Active, not recruiting

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL Recruiting

Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC Starting soon

BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression Enrolling by invitation

Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma Recruiting

Other trials for the same condition

Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC Recruiting

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC Recruiting

A Study of SH009 Injection in Patients With Advanced Solid Tumors. Recruiting

RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC Recruiting

Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07145931 on ClinicalTrials.gov ↗ ← All trials in China